Early T-cell precursor (ETP) phenotype (CD1a-, CD8-, CD5 weak, with myeloid/stem-cell mar...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | RF-T-ALL-HIGH-RISK-BIOLOGY |
|---|---|
| Type | Signal d’alerte |
| État | reviewed 2026-04-25 | pending_clinical_signoff |
| Maladies | DIS-T-ALL |
| Sources | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Origine du drapeau rouge
| Définition | Early T-cell precursor (ETP) phenotype (CD1a-, CD8-, CD5 weak, with myeloid/stem-cell markers) — historically inferior outcomes with standard T-ALL chemo; nelarabine + alloSCT consolidation considered. |
|---|---|
| Direction clinique | intensifier |
| Catégorie | high-risk-biology |
Logique de déclenchement
{
"any_of": [
{
"finding": "etp_phenotype",
"value": true
},
{
"finding": "etp_all",
"value": true
}
],
"type": "biomarker"
}
Notes
ETP-ALL is a WHO 2022 distinct entity. Modern MRD-stratified protocols (UKALL14, GRAALL) have closed much of the historical gap, but alloSCT eligibility remains the dominant decision — hence intensify.
Utilisé par
No reverse references found in the YAML corpus.